Global Life Science Ventures
Tal 26 D, München, Bayern, 80331, Germany
Overview
Global Life Science Ventures (GLSV) was a venture capital fund focusing exclusively on the life sciences. GLSV was dedicated to supporting early-stage groups, originating from universities, scientific institutions or industry. The fund also invested in selected later stage companies, including buy-outs. For this purpose, GLSV provided finance, advice and access to expertise and networks. The group advised and managed funds totaling more than € 200 million. With offices in Germany and Switzerland, GLSV acted as one team with a global perspective. The first fund started its activities in 1996 and invested in 18 companies. The second fund GLSV II started in 2001 and invested in 18 companies primarily in Europe and the US. After termination of the investment period, the fund exited the remaining assets in 2015 and is in liquidation.
- Total investments
- 3
- Lead investments
- 0
- Investments · 12mo
- 0
- Active investors
- 0
Sector focus
- Financial Services
- Life Science
- Venture Capital
Investment portfolio
- Nabriva Therapeutics
Participated · Series B · Apr 2015
Nabriva Therapeutics AG is a Vienna- and Philadelphia-based biotechnology company focused on the discovery and development of pleuromutilin antibiotics. Its lead product, lefamulin (BC‑3781), is the first systemically available pleuromutilin for human use and is entering pivotal phase 3 studies for community-acquired bacterial pneumonia (CABP). Lefamulin shows in vitro activity against the most common CABP pathogens, including S. pneumoniae, H. influenzae, M. catarrhalis, S. aureus, M. pneumoniae, L. pneumophila and C. pneumoniae, including multi-drug resistant strains. Preclinical programs include Extended Spectrum Pleuromutilins (ESPs), a new generation targeting CDC‑identified urgent and serious threats such as carbapenem-resistant Enterobacteriaceae (CRE). The company is led by CEO Dr Colin Broom. Nabriva completed a $120M Series B financing, with an initial $50M tranche to advance lefamulin into phase 3 studies and to continue pipeline development. Nabriva Therapeutics is a Vienna, Austria–based biotechnology company focused on developing a new class of antibiotics for serious infections caused by resistant pathogens. Its core program is a systemic pleuromutilin antibiotic program. The company plans to use funds to advance that program up to and including the generation of phase II efficacy data in the second half of 2010. Nabriva closed a €15M equity financing from existing investors to support development. The financing extends the company's cash reach into 2011, according to CEO Dr. David Chiswell. Since its foundation in 2006 the company has raised €57.4M (approximately $84M) in total equity funding.
- Action Pharma
Participated · Equity · Jun 2010
Action Pharma A/S is a Holte, Denmark-based biotech developing novel drug candidates that target melanocortin receptors. Its lead candidate, AP214, is being developed to protect against acute kidney injury in patients undergoing cardiac surgery with cardiopulmonary bypass. The company focuses on advancing programs to clinical proof of concept for subsequent partnering. It completed a €5m financing round from existing shareholders including Sunstone Capital, Global Life Science Ventures, SLS Invest and InnovationsKapital. The new capital will be used to advance ongoing phase 2a studies and to initiate a phase 2b study of AP214. Interim phase 2a efficacy and safety data were expected by the end of June 2010.
- Pieris AG
Participated · Series B · Mar 2008
Pieris AG is a clinical-stage biotechnology company advancing its proprietary Anticalin® platform to create differentiated protein therapeutics. The company received a €1m grant from the German Federal Ministry for Education and Research (BMBF) to support development of its PRS-110 compound targeting c-Met. The funded work will focus on delineating a biomarker strategy for early clinical development and advancing a personalized medicine approach for PRS-110. Pieris' pipeline includes lead compound PRS-050 (anti-VEGF), which recently completed a Phase I clinical trial, and multiple Anticalins in preclinical development across therapeutic areas. Pieris has signed four discovery and development collaborations with Daiichi Sankyo, Takeda San Francisco, the Sanofi Group and Allergan. The company is led by CEO Stephen Yoder and is backed by OrbiMed Advisors and Global Life Science Ventures. Pieris AG develops Anticalins, an engineered class of targeted human proteins derived from human lipocalin scaffolds. Anticalins are small (≈20 kDa), human‑origin binding proteins designed to offer antibody‑like selectivity and affinity with low immunogenicity, robust physicochemical properties, high solubility and stability, and advantageous tissue penetration. Pieris exclusively owns the Anticalin patent estate and applies protein engineering as part of a balanced risk business model to advance product candidates. The company is prioritising clinical development of PRS‑050, a VEGF‑modulating cancer candidate that has shown preclinical anti‑tumour activity and is being prepared for a Phase I study. Pieris recently raised €25 million (US$38M) in a Series B financing to progress its proprietary Anticalin portfolio and advance clinical priorities. The financing is intended to position Anticalins as a next class of biopharmaceutical products.
Team
No current team members are available.